The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat
Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases
Dozee plans to further tap over 2,000 hospitals in more than 100 districts
The company sees the business reaching $100mn
Roy is the right successor to lead Philips’ efforts to help improve the health and well-being of people globally
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
The Supervisory Board has unanimously decided to propose Roy Jakobs as the next President and CEO of Royal Philips to its General Meeting of Shareholders.
Steps afoot to make RRIH & RRIUM as a Centres of Excellence for Allergic Disorder and for Regimental Therapy respectively
States have an important role in ensuring food safety and healthy food practices.
Subscribe To Our Newsletter & Stay Updated
